Orlistat (Xenical)

A lactone derivative of LEUCINE that acts as a pancreatic lipase inhibitor to limit the absorption of dietary fat; it is used in the management of obesity.

Also Known As:

Xenical; 1-((3-Hexyl-4-oxo-2-oxetanyl)methyl)dodecyl-2-formamido-4-methylvalerate; Alli; Ro-18-0647; THLP; Tetrahydrolipastatin; Tetrahydrolipstatin; Ro 18 0647; L-Leucine, N-formyl-, 1-((3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester, (2S-(2alpha(R*),3beta))-

Networked: 1156 relevant articles (195 outcomes, 333 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 133
- Lactones: 1549
  - Orlistat: 1156

Experts

1.	Tziomalos, Konstantinos: 10 articles (12/2018 - 05/2006)
2.	Filippatos, T D: 9 articles (10/2010 - 02/2005)
3.	Graner, Edgard: 8 articles (09/2021 - 12/2008)
4.	Katsikis, Ilias: 8 articles (03/2014 - 01/2007)
5.	Panidis, Dimitrios: 8 articles (03/2014 - 01/2007)
6.	Elisaf, Moses S: 8 articles (11/2011 - 05/2006)
7.	Elisaf, M S: 8 articles (10/2010 - 02/2005)
8.	Grilo, Carlos M: 7 articles (12/2021 - 05/2005)
9.	Aronne, Louis J: 7 articles (01/2019 - 12/2003)
10.	Bray, George A: 7 articles (08/2014 - 06/2002)

Related Diseases

1.	Weight Loss (Weight Reduction) 01/01/1998 - "Orlistat, an inhibitor of pancreatic lipases, has proven effective for weight reduction in obese patients. " 01/01/2006 - "The weight loss was significantly greater in the orlistat group than in the placebo group for the entire study period (P < 0.001). " 12/01/2005 - "Orlistat-treated patients achieved significantly greater weight loss at the study end than placebo-treated patients (-5.4 vs. -2.4 kg; P<0.0001). " 01/01/2003 - "In randomized, controlled trials of up to 2 years' duration, orlistat plus a hypocaloric diet produced significantly greater weight loss than placebo (P < 0.001). " 08/01/1998 - "In 2-year studies, weight loss was significantly greater in orlistat than in placebo recipients by the end of year 1; weight was further reduced or maintained in the second year, when a eucaloric diet was allowed, in orlistat but not placebo recipients. "
2.	Obesity 01/01/2006 - "Xenical is beneficial for patients with DM-2 and obesity because it improves metabolic processes." 01/01/2002 - "[Efficacy of orlistat in the treatment of constitutional-alimentary obesity in patients with high risk of cardiovascular complications]." 01/01/2000 - "Several obesity-related risk factors improved significantly more with orlistat treatment than with placebo. " 10/25/2023 - "Black garlic provides a reliable and effective treatment for obesity compared to orlistat." 03/01/2009 - "Orlistat, an inhibitor of digestive lipases, is widely used for the treatment of obesity. "
3.	Type 2 Diabetes Mellitus (MODY) 01/01/2005 - "In obese patients, orlistat in combination with a hypocaloric diet improved metabolic risk factors and reduced the risk of developing type 2 diabetes. " 01/01/2004 - "In obese patients, orlistat in combination with a hypocaloric diet improved metabolic risk factors and reduced the risk of developing type 2 diabetes. " 12/01/2015 - "Inclusion criteria included all randomized controlled trials of orlistat carried out on adult participants with a body mass index of 25 kg m(-2) or over diagnosed with type 2 diabetes, which reported weight change and at least one diabetic outcome. " 12/01/2015 - "A systematic review of randomized controlled trials of orlistat in people with type 2 diabetes reporting diabetes outcomes in studies published between January 1990 and September 2013 was conducted. " 05/01/2005 - "The aim of this study is to review the clinical and economic rationale for the reimbursement of orlistat in responding obese patients with type 2 diabetes. "
4.	Body Weight (Weight, Body) 06/01/2016 - "The present results suggest that orlistat leads to significant reduction in BMI/body weight in PCOS. " 01/01/2010 - "We also recorded a significant reduction of body weight and BMI with orlistat, but not with placebo. " 04/01/1998 - "Orlistat resulted in a significantly greater mean loss of body weight than observed in the placebo group. " 04/01/2005 - "The aim of this study was to assess safety, tolerability and efficacy of orlistat treatment in comparison with placebo in the reduction of body weight in obese subjects and the related cardiovascular risk factors. " 01/01/2003 - "The results of this study demonstrate that orlistat improved endothelial function, weight, body mass index and systolic and diastolic blood pressure in young women."
5.	Overweight 06/01/2016 - "Data suggest that orlistat promotes a significant reduction in BMI/weight in overweight/obese PCOS women. " 07/01/2022 - "This is the first study found that EE/DRSP plus Orlistat could significantly decrease Lp(a) in overweight or obese PCOS patients. " 07/18/2018 - "The results of this study will provide evidence for the effect of preconceptional orlistat treatment on IVF outcome in overweight/obese women. " 07/18/2018 - "Effect of preconceptional orlistat treatment on in-vitro fertilization outcome in overweight/obese women: study protocol for a randomized controlled trial." 04/01/2014 - "The primary objective of this study was to evaluate the effect of orlistat on the weight and body mass index of obese and overweight Korean patients. "

Related Drugs and Biologics

1.	sibutramine (Meridia)
2.	Lipids
3.	Glucose (Dextrose)
4.	Metformin (Glucophage)
5.	Anti-Obesity Agents (Antiobesity Drugs)
6.	Triglycerides (Triacylglycerol)
7.	Cholesterol
8.	Lipase (Acid Lipase)
9.	Liraglutide
10.	Insulin (Novolin)

Related Therapies and Procedures

1.	Therapeutics
2.	Glycemic Control
3.	Caloric Restriction
4.	Fat-Restricted Diet (Diet, Fat Restricted)
5.	Drug Therapy (Chemotherapy)